Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.1890
+0.0040 (2.16%)
At close: Oct 9, 2026
Integrated BioPharma Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 4.47 | 3.62 | 1.68 | 1.32 | 0.33 |
Short-Term Investments | - | - | - | - | 0.01 |
Cash & Short-Term Investments | 4.47 | 3.62 | 1.68 | 1.32 | 0.34 |
Cash Growth | 23.68% | 115.56% | 27.43% | 283.67% | 23.83% |
Receivables | 3.33 | 5.43 | 4.67 | 4.51 | 4.89 |
Inventory | 9.14 | 9.36 | 11.24 | 10.26 | 11.06 |
Other Current Assets | 0.43 | 0.36 | 0.29 | 0.28 | 0.34 |
Total Current Assets | 17.38 | 18.76 | 17.88 | 16.37 | 16.63 |
Property, Plant & Equipment | 4.83 | 2.75 | 3.68 | 4.28 | 3.78 |
Long-Term Deferred Tax Assets | 3.08 | 3.34 | 4.6 | 4.73 | 4.8 |
Other Long-Term Assets | 0.05 | 0.05 | 0.06 | 0.06 | 0.05 |
Total Assets | 25.34 | 24.9 | 26.21 | 25.43 | 25.25 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 3.2 | 2.27 | 2.51 | 2.27 | 3.21 |
Accrued Expenses | 1.39 | 1.3 | 2.66 | 1.63 | 1.41 |
Short-Term Debt | - | - | - | - | 0.1 |
Current Portion of Long-Term Debt | - | - | - | - | 0.03 |
Current Portion of Leases | 1.21 | 0.68 | 0.95 | 0.93 | 0.51 |
Total Current Liabilities | 5.8 | 4.25 | 6.12 | 4.83 | 5.26 |
Long-Term Debt | - | - | - | - | 0.05 |
Long-Term Leases | 1.87 | 0.34 | 0.85 | 1.74 | 1.36 |
Total Liabilities | 7.67 | 4.58 | 6.97 | 6.57 | 6.68 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
Additional Paid-In Capital | 51.97 | 51.77 | 51.5 | 51.24 | 50.92 |
Retained Earnings | -34.26 | -31.42 | -32.23 | -32.34 | -32.31 |
Treasury Stock | -0.1 | -0.1 | -0.1 | -0.1 | -0.1 |
Shareholders' Equity | 17.67 | 20.32 | 19.24 | 18.86 | 18.58 |
Total Liabilities & Equity | 25.34 | 24.9 | 26.21 | 25.43 | 25.25 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 3.08 | 1.02 | 1.8 | 2.67 | 2.06 |
Net Cash (Debt) | 1.39 | 2.6 | -0.12 | -1.36 | -1.71 |
Net Cash Growth | -46.42% | - | - | - | - |
Net Cash Per Share | 0.04 | 0.08 | -0.00 | -0.05 | -0.05 |
Filing Date Shares Outstanding | 31.06 | 31.06 | 30.1 | 29.95 | 29.95 |
Total Common Shares Outstanding | 31.06 | 31.06 | 30.1 | 29.95 | 29.95 |
Working Capital | 11.58 | 14.52 | 11.75 | 11.54 | 11.36 |
Book Value Per Share | 0.57 | 0.65 | 0.64 | 0.63 | 0.62 |
Tangible Book Value | 17.67 | 20.32 | 19.24 | 18.86 | 18.58 |
Tangible Book Value Per Share | 0.57 | 0.65 | 0.64 | 0.63 | 0.62 |
Land | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
Machinery | 7.38 | 7.25 | 7.11 | 6.8 | 6.73 |
Leasehold Improvements | 1.55 | 1.41 | 1.34 | 1.37 | 1.37 |